Want to join the conversation?
Specialty chemicals maker $EMN reported a rise in 1Q16 earnings driven by lower costs and expenses despite a decline in sales due to decline in Chemical Intermediates. Net income rose to $251MM or $1.69 per share from $171MM or $1.14 per share last year. Sales fell to $2.24Bil from $2.44Bil. Excluding non-core items, EPS slid to $1.71 from $1.84.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.